Active Filter(s):
Details:
U.S. Food and Drug Administration (FDA) has cleared the Cliniporator platform for use in the upcoming Phase 1 trial to be held at Providence Health investigating CORVax12, the Company's DNA-encodable vaccine candidate for COVID-19.
Lead Product(s): CORVax12
Therapeutic Area: Infections and Infectious Diseases Product Name: CORVax12
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: OncoSec Medical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 24, 2020